Advertisement

Non-NSAID pharmacologic treatment options for the management of chronic pain

  • Thomas J Schnitzer
    Correspondence
    Requests for reprints should be addressed to Thomas J. Schnitzer, MD, PhD, Office of Clinical Research and Training, Northwestern University, Abbott Hall, 5th Floor, 710 N. Lakeshore Drive, Chicago, Illinois 60611
    Affiliations
    Office of Clinical Research and Training, Northwestern University, Chicago, Illinois, USA
    Search for articles by this author

      Abstract

      Chronic pain affects 75 million US citizens. A number of pharmacologic treatments are available for chronic pain that does not respond adequately to nonpharmacologic methods. Long the mainstay of chronic pain management, nonsteroidal anti-inflammatory drugs (NSAIDs) are known to be associated with gastrointestinal (GI) and renal toxicities, a particular problem for the elderly population, which commonly experiences chronic pain, such as that associated with osteoarthritis (OA). Several non-NSAID, non-narcotic therapies are available for noninflammatory pain. Acetaminophen is as effective as NSAIDs for the management of mild-to-moderate OA pain and is the recommended first-line therapy by the American College of Rheumatology (ACR). Propoxyphene, widely believed to be safe and effective, may, in fact, be no more effective—and perhaps less effective—than acetaminophen or ibuprofen. A relatively new analgesic, tramadol, appears to be a useful therapy for patients who do not receive adequate pain relief with acetaminophen and are at risk for NSAID-related side effects. For localized chronic pain associated with OA, topical capsaicin is also an effective analgesic.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Flynn B.L
        Rheumatoid arthritis and osteoarthritis.
        Am Pharm. 1994; 34: 1-8
      1. Caudill MA, Holman GH, Turk D. Effective ways to manage chronic pain. Patient Care. June 1996:154–172.

        • Conaway D.C
        Using NSAIDs safely in the elderly.
        Hosp Med. May. 1995; 31: 23-34
        • Griffin M.R
        • Piper J.M
        • Daugherty J.R
        • et al.
        Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.
        Ann Intern Med. 1991; 114: 257-263
        • Henry D
        • Dobson A
        • Turner C
        Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.
        Gastroenterology. 1993; 105: 1078-1088
        • Whelton A
        • Hamilton C.W
        Nonsteroidal anti-inflammatory drugs.
        J Clin Pharmacol. 1991; 31: 588-598
        • Muir H
        Current and future trends in articular cartilage research and osteoarthritis.
        in: Kuertner K.E Schleyerbach R Hascall V.C Articular Cartilage Biochemistry. Raven Press, New York1986: 423-440
        • Bayliss M.T
        Proteoglycan structure in normal and osteoarthrotic human cartilage.
        in: Kuertner K.E Schleyerbach R Hascall V.C Articular Cartilage Biochemistry. Raven Press, New York1986: 295-310
        • Hochberg M.C
        • Altman R.D
        • Brandt K.D
        • et al.
        Guidelines for the medical management of osteoarthritis. Part I.
        Arthritis Rheum. 1995; 38: 1535-1540
        • Hochberg M.C
        • Altman R.D
        • Brandt K.D
        • et al.
        Guidelines for the medical management of osteoarthritis. Part II.
        Arthritis Rheum. 1995; 38: 1541-1546
        • Bradley J.D
        • Brandt K.D
        • Katz B.P
        • et al.
        Treatment of knee osteoarthritis.
        J Rheumatol. 1992; 19: 1550-1554
        • Schnitzer T.J
        Osteoarthritis treatment update. Minimizing pain while limiting patient risk.
        Postgrad Med. 1993; 93: 89-92
        • Schnitzer T.J
        • Andriachhi T.P
        • Fedder D
        • et al.
        Effect of NSAIDs on knee loading in patients with osteoarthritis (Abstr.).
        Arthritis Rheum. 1990; 33: 592
        • Ghosh P
        Anti-rheumatic drugs and cartilage.
        Baillieres Clin Rheumatol. 1980; 19: 212-217
        • Williams H.J
        • Ward J.R
        • Egger J.M
        • et al.
        Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee.
        Arthritis Rheum. 1993; 36: 1196-1206
        • Flower R.J
        • Vane J.R
        Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol).
        Nature. 1972; 240: 410-411
      2. Physician’s Desk Reference. 51st ed. Montvale, NJ: Medical Economics Company, 1997:1570–1571.

        • Nelson S.D
        Molecular mechanisms of the hepatotoxicity caused by acetaminophen.
        Semin Liver Dis. 1990; 10: 267-278
        • Bradley J.D
        • Brandt K.D
        • Katz B.P
        • Kalasinski L.A
        • Ryan S.I
        Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
        N Engl J Med. 1991; 325: 87-91
        • Vickers F.N
        Mucosal effects of aspirin and acetaminophen.
        Gastrointest Endosc. 1967; 14: 94-99
        • Henrich W.L
        • Agodos L.E
        • Barrett B
        Analgesics and the kidney.
        Am J Kidney Dis. 1996; 27: 162-165
        • Johnston S.C
        • Pelletier Jr, L.L
        Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature.
        Medicine. 1997; 76: 185-191
        • Schiodt F.V
        • Rochling F.A
        • Casey D.L
        • Lee W.M
        Acetaminophen toxicity in an urban county hospital.
        N Engl J Med. 1997; 337: 1112-1117
        • Benson G.D
        Hepatotoxicity following the therapeutic use of antipyretic analgesics.
        Am J Med. 1983; 75: 85-93
        • Forrest J.A.H
        • Adriaenssens P
        • Finlayson N.D.C
        • Prescott L.F
        Paracetamol metabolism in chronic liver disease.
        Eur J Clin Pharmacol. 1979; 15: 427-431
        • Andreasen P.B
        • Hutters L
        Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver.
        Acta Med Scand. 1979; 624: 99-105
        • Gabrielle L
        • Leterrier F
        • Molinie C
        • et al.
        Determination of human liver cytochrome P-450 by a micromethod using electron paramagnetic resonance. Study of 141 liver biopsies.
        Gastroenterol Clin Biol. 1977; 1: 775-782
        • Farrell G.C
        • Cooksley W.G.E
        • Powell L.W
        Drug metabolism in liver disease.
        Clin Pharmacol Ther. 1979; 26: 483-492
        • Forrest J.A.H
        • Finlayson N.D.C
        • Adjepon-Yamoah K.K
        • Prescott L.F
        Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
        BMJ. 1977; 1: 1384-1387
        • Shamszad M
        • Soloman H
        • Mobarhan S
        • Iber F.L
        Abnormal metabolism of acetaminophen in patients with alcoholic liver disease (Abstr.).
        Gastroenterology. 1975; A-65: 865
        • Arnman R
        • Olsson R
        Elimination of paracetamol in chronic liver disease.
        Acta Hepatogastroenterol (Stuttg). 1978; 25: 283-286
        • Raffa R.B
        • Friderichs E
        • Reimann W
        • Shank R.P
        • Codd E.E
        • Vaught J.L
        Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic.
        J Pharmacol Exp Ther. 1992; 260: 275-285
        • Driessen B
        • Reimann W
        • Giertz H
        Effect of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro.
        Br J Pharmacol. 1993; 108: 806-811
        • Katz W.A
        The role of tramadol in the management of musculoskeletal pain.
        Today’s Ther Trends. 1995; 13: 177-186
        • Raffa R.B
        • Friderichs E
        • Reimann W
        • et al.
        Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol.
        J Pharmacol Exp Ther. 1993; 267: 331-340
      3. Physicians’ Desk Reference. 51st ed. Montvale, NJ: Medical Economics Company; 1997:1594–1599.

      4. Dalgin P. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis. Presented at the National Scientific Meeting, American College of Rheumatology; November 8–12, 1997; Washington, DC.

      5. Roth SH. Efficacy and safety of tramadol HCI in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. Forthcoming 1998;25 (in press).

      6. Schnitzer T, Kamin M. Ultram® (tramadol HCl) maintains relief of osteoarthritis (OA) pain when substituted for high dose naproxen. Presented at the National Scientific Meeting, the American College of Rheumatology; November 8–12, 1997; Washington, DC.

      7. Russell IJ, Kamin M, Sager D, et al. Efficacy of Ultram® (tramadol HCl) treatment of fibromyalgia syndrome: preliminary analysis of a multi-center, randomized, placebo-controlled study. Presented at the National Scientific Meeting, American College of Rheumatology; November 8–12, 1997; Washington, DC.

        • Dalgin P.H
        Use of tramadol in chronic pain.
        Clin Geriatr. 1995; 3: 17-30
        • Barkin R.L
        Alternative dosing for tramadol aids effectiveness.
        Formulary. 1995; 30: 542-543
      8. Ruoff G. An evaluation of varying titration rates of tramadol in patients with chronic joint pain. Pharmacotherapy 1998 (in press).

        • Grover H
        Propoxyphene.
        J Indian Med Assoc. 1988; 86: 21-23
      9. US GAO Report to the Honorable Ron Wyden, House of Representatives: Prescription Drugs and the Elderly. GAO/HEHS-95–152. US General Accounting Office, Health Education and Human Services Division, July 1995.

        • Willcox S.M
        • Himmelstein D.U
        • Woolhandler S
        Inappropriate drug prescribing for the community-dwelling elderly.
        JAMA. 1994; 272: 292-296
        • Mapp P
        • Kidd B
        The role of substance P in rheumatic disease.
        Semin Arthritis Rheum. 1994; 23: 3-9
        • Lotz M
        Experimental models of arthritis.
        Semin Arthritis Rheum. 1994; 23: 10-17
        • Deal C.L
        • Schnitzer T.J
        • Lipstein E
        • et al.
        Treatment of arthritis with topical capsaicin.
        Clin Ther. 1991; 13: 383-395
        • McCarthy G.M
        • McCarty D.J
        Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands.
        J Rheumatol. 1992; 19: 604-607
        • Schnitzer T.J
        • Morton C
        • Coker S
        Topical capsaicin therapy for osteoarthritis pain.
        Semin Arthritis Rheum. 1994; 23: 34-40
        • Altman R.D
        • Aven A
        • Holmburg C.E
        • et al.
        Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study.
        Semin Arthritis Rheum. 1994; 23: 25-33
        • Zhang W.Y
        • Li Wan Po A
        The effectiveness of topically applied capsaicin. A meta-analysis.
        Eur J Clin Pharmacol. 1994; 46: 517-522
        • Tolman K.G
        Hepatotoxicity of non-narcotic analgesics.
        Am J Med. 1998; 105: 13-19